NPI: 1205488996 · PENNINGTON GAP, VA 24277 · Critical Access Hospital · NPI assigned 07/12/2019
Authorized official HILTON, SHANE controls 20+ related entities in our dataset. Read more
| Authorized Official | HILTON, SHANE (EVP/CFO) |
| NPI Enumeration Date | 07/12/2019 |
Other providers sharing the same authorized official: HILTON, SHANE
| Year | Claims | Total Paid |
|---|---|---|
| 2021 | 13,572 | $667K |
| 2022 | 35,131 | $2.18M |
| 2023 | 35,394 | $2.97M |
| 2024 | 27,180 | $2.46M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 11,954 | 10,760 | $2.97M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 6,431 | 5,844 | $1.41M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3,431 | 3,060 | $844K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1,721 | 1,460 | $632K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 5,793 | 5,390 | $472K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1,883 | 1,755 | $382K |
| 70450 | Computed tomography, head or brain; without contrast material | 1,179 | 1,082 | $342K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 989 | 924 | $271K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 925 | 868 | $239K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1,171 | 1,063 | $118K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 966 | 882 | $87K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 200 | 182 | $62K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 175 | 161 | $57K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 161 | 127 | $49K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 77 | 76 | $45K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 995 | 894 | $33K |
| 80053 | Comprehensive metabolic panel | 6,092 | 5,220 | $26K |
| 71046 | Radiologic examination, chest; 2 views | 1,776 | 1,680 | $25K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1,706 | 1,573 | $24K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 136 | 130 | $22K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3,867 | 3,206 | $14K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2,622 | 2,465 | $12K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 623 | 560 | $8K |
| 71045 | Radiologic examination, chest; single view | 2,679 | 2,392 | $8K |
| 83880 | 847 | 760 | $8K | |
| 87040 | 1,743 | 889 | $7K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3,157 | 2,827 | $7K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6,737 | 5,697 | $7K |
| 36415 | Collection of venous blood by venipuncture | 2,091 | 1,850 | $5K |
| 81025 | 1,328 | 1,230 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 2,539 | 2,110 | $5K |
| 73562 | 303 | 291 | $5K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1,479 | 1,299 | $5K |
| 72100 | 153 | 147 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 14 | 14 | $4K |
| 73630 | 425 | 396 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | 85 | 78 | $4K |
| 84443 | Thyroid stimulating hormone (TSH) | 516 | 493 | $4K |
| 81001 | 2,622 | 2,373 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2,170 | 1,962 | $3K |
| 90715 | 98 | 93 | $3K | |
| 74018 | 109 | 106 | $3K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 27 | 24 | $2K |
| 85379 | 727 | 682 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 115 | 112 | $2K |
| 84484 | 2,792 | 2,194 | $2K | |
| 96376 | 772 | 606 | $2K | |
| 73130 | 184 | 176 | $2K | |
| 81003 | 1,852 | 1,697 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 128 | 119 | $2K |
| 73610 | 248 | 230 | $2K | |
| 73030 | 106 | 101 | $1K | |
| 83735 | 1,353 | 1,147 | $1K | |
| 73110 | 84 | 78 | $923.40 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 86 | 85 | $816.52 |
| 74022 | 114 | 108 | $811.09 | |
| 80143 | 159 | 143 | $772.82 | |
| 85027 | 677 | 623 | $751.78 | |
| 71250 | 15 | 15 | $743.62 | |
| 83605 | 1,473 | 1,059 | $733.65 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1,672 | 1,438 | $715.69 |
| 83690 | 1,951 | 1,763 | $705.37 | |
| 94760 | 908 | 803 | $688.74 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 943 | 860 | $668.17 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 128 | 107 | $594.46 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1,214 | 1,044 | $541.09 |
| 80179 | 158 | 143 | $532.63 | |
| 36600 | 166 | 145 | $450.66 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1,328 | 1,174 | $384.64 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 564 | 457 | $355.63 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1,807 | 1,636 | $339.79 |
| 80061 | Lipid panel | 43 | 40 | $334.37 |
| 87186 | 341 | 304 | $288.19 | |
| 82805 | 52 | 46 | $280.49 | |
| 85610 | 389 | 348 | $239.63 | |
| 87077 | 316 | 292 | $197.23 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 178 | 135 | $176.58 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 97 | 77 | $165.10 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 993 | 935 | $155.55 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 187 | 175 | $153.28 |
| 83036 | Hemoglobin; glycosylated (A1C) | 32 | 29 | $138.23 |
| 82803 | 222 | 143 | $93.24 | |
| 87081 | 930 | 874 | $80.53 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 746 | 352 | $54.48 |
| 82375 | 52 | 46 | $53.66 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 41 | 40 | $51.31 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 38 | 34 | $50.43 |
| 84703 | 73 | 68 | $34.63 | |
| J2060 | Injection, lorazepam, 2 mg | 96 | 80 | $32.95 |
| 83050 | 52 | 46 | $31.35 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 80 | 76 | $27.66 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 355 | 343 | $22.34 |
| 84439 | 12 | 12 | $18.26 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 78 | 72 | $4.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 57 | 46 | $1.92 |
| J1940 | Injection, furosemide, up to 20 mg | 17 | 12 | $1.20 |
| J1815 | Injection, insulin, per 5 units | 23 | 12 | $0.48 |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 14 | 13 | $0.00 |
| 85007 | 14 | 14 | $0.00 | |
| 87205 | 15 | 12 | $0.00 | |
| 87070 | 15 | 12 | $0.00 |